Evidence map›Paper›PMID 40346697›Full record

ArticleStem cell research & therapy2025

Functional analysis of JPH2-knockout cardiomyocytes identifies ECCD as a novel indicator in a human cardiac modelJPH2.

Tianwei Guo, Hongyue Wang, Fujian Wu, Wenjing Lu, Min Zhu, Shuhong Ma, Yongshuai Zhang, Yuting Yan, Meng Zhou, Didaer Talanaite and 4 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tianwei Guo *Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Hongyue Wang *Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Fujian Wu *Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Wenjing LuBeijing Laboratory for Cardiovascular Precision Medicine, The Key Laboratory of Biomedical Engineering for Cardiovascular Disease Research, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Min ZhuState Key Laboratory of Cardiovascular Disease, Key Laboratory of Pluripotent Stem Cells in Cardiac Repair and Regeneration, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Beilishi Road, Xicheng District, Beijing, 100037, China.
Shuhong MaFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Yongshuai ZhangState Key Laboratory of Cardiovascular Disease, Key Laboratory of Pluripotent Stem Cells in Cardiac Repair and Regeneration, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Beilishi Road, Xicheng District, Beijing, 100037, China.
Yuting YanFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Meng ZhouFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Didaer TalanaiteFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Siyu LiuFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China.
Man QiFuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Center for Cardiovascular Diseases, No. 167 Beilishi Road Xicheng District, Beijing, 100037, China. qimandonkey@163.com.
Feng LanFuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen Key Laboratory of Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Key Laboratory of Pluripotent Stem Cells in Cardiac Repair and Regeneration, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China. fenglan@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-9038-4014
Xujie LiuState Key Laboratory of Cardiovascular Disease, Fuwai Hospital Chinese Academy of Medical Sciences, No. 12 Langshan Road, Nanshan District, Shenzhen, Guangdong Province, 518057, China. liuxujie@fuwaisz.cn.

Funding

CAMS Innovation Fund for Medical Sciences 2021-RC310-12, 2022I2M-2-001 and 2023-I2M-1-003China Postdoctoral Science Foundation 2024T170070Chinese PLA General Hospital Sixth medical center Innovation and Culture Grant CXPY202304National High-Level Hospital Clinical Research Funding 2022-GSP-GG-7National Key Research and Devel opment Program of China 2021YFC2701703, 2023YFA0915002National Natural Science Foundation of China 82400381Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2019PT320026Open Project Fund of National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital NCRCG-PLAGH-2024008Open Project Fund of State Key Laboratory of Cardiovascular Diseases,Shanghai East Hospital 2024SKL-TJ001Shenzhen Fundamental Research Program ZDSYS20200923172000001
6 · The paper itself

Abstract

backgroundJunctophilin-2 (JPH2) is a vital protein in cardiomyocytes, anchoring T-tubule and sarcoplasmic reticulum membranes to facilitate excitation-contraction coupling, a process essential for cardiac contractile function. Dysfunction of JPH2 is associated with cardiac disorders such as heart failure; however, prior studies using mouse models or primary human cardiomyocytes are limited by interspecies differences or poor cell viability, respectively. This study aimed to investigate JPH2's role in human cardiac function and disease using a novel stem cell-derived model, while introducing a new indicator to evaluate related cardiac impairments.

methodsWe generated a JPH2-knockout model using human embryonic stem cell-derived cardiomyocytes (hESC-CMs) with CRISPR/Cas9. Cellular morphology, contractile function, calcium dynamics, and electrophysiological properties were assessed via transmission electron microscopy, the CardioExcyte96 system, calcium imaging with Fluo-4 AM, and multi-electrode array recordings, respectively. Wild-type JPH2 was overexpressed through lentiviral transfection to evaluate rescue effects, and two JPH2 variants-one benign (G505S) and one pathogenic (E85K)-were introduced to study mutation-specific effects.

resultsJPH2 knockout disrupted excitation-contraction coupling in hESC-CMs by impairing junctional membrane complex structure, leading to heart failure-like phenotypes with reduced contractility, altered calcium dynamics, and electrophysiological irregularities. Overexpression of wild-type JPH2 restored these functions, affirming its critical role in cardiac physiology. We identified excitation-contraction coupling delay (ECCD) as a novel indicator that precisely quantified coupling impairment severity, with its applicability validated across distinct JPH2 variants (G505S and E85K).

conclusionsThis study demonstrates JPH2's essential role in sustaining excitation-contraction coupling by stabilizing the junctional membrane complex, with its deficiency driving heart failure-like cardiac dysfunction. ECCD is established as a sensitive, comprehensive indicator for assessing JPH2-related impairment severity. These findings advance our understanding of JPH2 in cardiac pathology and position ECCD as a valuable tool for research and potential clinical evaluation, with JPH2 and calcium regulation emerging as promising therapeutic targets.

Indexed as

Excitation Contraction CouplingMembrane ProteinsMyocytes, CardiacAnimalsCalciumCRISPR-Cas SystemsHuman Embryonic Stem CellsHumansMuscle ProteinsMyocardial ContractionCalciumJPH2 protein, humanMembrane ProteinsMuscle ProteinsCardiomyopathyExcitation-contraction couplingHuman embryonic stem cell-derived cardiomyocytesJunctophilin 2

Identifiers

PMID40346697
PMCPMC12065164

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.